Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Summit Therapeutics Inc (NASDAQ: SMMT) was $23.87 for the day, up 3.38% from the previous closing price of $23.09. In other words, the price has increased by $3.38 from its previous closing price. On the day, 1.65 million shares were traded.
Ratios:
Our analysis of SMMT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 10.63 and its Current Ratio is at 10.63. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Citigroup on March 26, 2025, Upgraded its rating to Buy and sets its target price to $35 from $23 previously.
On March 12, 2025, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $30.Evercore ISI initiated its Outperform rating on March 12, 2025, with a $30 target price.
Stock Price History:
Over the past 52 weeks, SMMT has reached a high of $36.91, while it has fallen to a 52-week low of $2.10. The 50-Day Moving Average of the stock is 6.65%, while the 200-Day Moving Average is calculated to be 21.38%.
Shares Statistics:
A total of 741.61M shares are outstanding, with a floating share count of 110.45M. Insiders hold about 85.03% of the company’s shares, while institutions hold 13.22% stake in the company.
Earnings Estimates
Investors are keenly observing as 7.0 analysts analyze and rate the current performance of Summit Therapeutics Inc (SMMT) in the stock market.The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.07 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.27 and -$0.35 for the fiscal current year, implying an average EPS of -$0.3. EPS for the following year is -$0.38, with 7.0 analysts recommending between -$0.31 and -$0.47.
Revenue Estimates
Based on 10 analysts’ estimates, the company’s revenue will be $17.82M in the next fiscal year. The high estimate is $162.11M and the low estimate is -$42.88M.
